Parian Ultreia LP Reports New 5.3% Stake in Exagen Inc. (XGN)

On May 27, 2026, Parian Ultreia LP filed a Schedule 13G with the SEC, reporting a new 5.3% ownership stake in Exagen Inc. (XGN). The filing indicates that as of the event date on May 22, 2026, Parian Ultreia LP beneficially owns 1,292,000 shares of the issuer's common stock. This position represents a significant new holding for the Delaware-based partnership, which previously held no shares. According to the filing details, Parian Ultreia LP maintains sole voting and dispositive power over all 1,292,000 shares. The reporting person is classified as a partnership (PN) and is located in Telluride, Colorado. The filing was executed by Zach Miller in his capacity as Portfolio Manager. This transaction crosses the 5% threshold, requiring the public disclosure of the firm's passive investment in the Vista, California-based life sciences company. The total value of the position at the time of reporting is estimated at approximately $5.97 million.